This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

NICE guidance - boceprevir for the treatment of genotype 1 chronic hepatitis C

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Boceprevir in combination with peginterferon alfa and ribavirin is recommended as an option for the treatment of genotype 1 chronic hepatitis C in adults with compensated liver disease:

  • who are previously untreated or in whom previous treatment has failed

Notes:

  • Boceprevir is a NS3/4A serine protease inhibitor that is administered orally
    • NS3/ 4A serine protease is essential for viral replication and may be partially responsible for the ability of the hepatitis C virus (HCV) to evade clearance by the host immune system
    • Boceprevir has a UK marketing authorisation 'for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy'

Reference:

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.